Patent intelligence · EP
EP 2846808
ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM
ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM
Patent details — EP 2846808
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Mar 18, 2015
- Expiration
- Mar 13, 2035
- Applicant
- CSL BEHRING GMBH [DE]
- CPC classes
- A61K 31/ 70 A I, A61K 31/ 7004 A I, A61K 31/ 7008 A I, A61K 31/ 7016 A I
Quick answer
EP 2846808 (ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Mar 18, 2015. Expires Mar 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CSL BEHRING GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 70 A I, A61K 31/ 7004 A I, A61K 31/ 7008 A I, A61K 31/ 7016 A I, A61K 38/ 17 A I, A61K/3170
More from CSL BEHRING GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2022258590
PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN
granted -
CA 3198740
METHODES DE TRAITEMENT D'UN REJET A MEDIATION PAR ANTICORPS
granted -
AU 2017305856
Pharmaceutical formulations of C1 esterase inhibitor
granted -
DK 2928905
FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER
granted -
CA 3072003
PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND
granted -
US 2018264111
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS
granted -
CA 3046406
PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES
granted -
CA 3034568
PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE
granted
Frequently asked questions
What is US patent 2846808?
EP 2846808 (ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM) is held by CSL BEHRING GMBH [DE]. Status: granted. Granted Mar 18, 2015. Expires Mar 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2846808?
CSL BEHRING GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2846808 expire?
Our index shows an expiration date of Mar 13, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.